CONTINUOUS ARYCYCLIC COMPOUND

摘要

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.;

主权项

1. A continuous arycyclic compound represented by the formula: wherein Alk represents a linear C1-6 alkylene group, a branched C1-6 alkylene group or a C1-6 alkylene group having a ring structure; where a part of the carbon atoms constituting the ring structure may be optionally substituted by an oxygen atom, a nitrogen atom or a sulfur atom, in Ring X, X1 represents N or CRX1, X2 represents N or CRX2, X3 represents N or CRX3, X4 represents N or CRX4, where RX1, RX2, RX3 and RX4 each independently represents a hydrogen atom; a linear or branched C1-6 alkyl group which may be substituted by a halogen atom(s); a C3-7 alkyl group having a ring structure which may be substituted by a halogen atom(s); a linear or branched C1-6 alkoxy group; a halogen atom or a cyano group, in Ring Y, Y1 represents N or CRY1, Y2 represents N or CRY2, Y3 represents N or CRY3, Y4 represents N or CRY4, RY1, RY2, RY3 and RY4 each independently represents a hydrogen atom; a linear or branched C1-6 alkyl group which may be substituted by a halogen atom(s); a C3-7 alkyl group having a ring structure which may be substituted by a halogen atom(s); a linear or branched C1-6 alkoxy group; a halogen atom or a cyano group, in Ring Z, RZ represents a linear or branched C1-6 alkyl group which may be substituted by a halogen atom(s) or C3-7 alkyl group having a ring structure which may be substituted by a halogen atom(s), or a pharmaceutically acceptable salt thereof, provided that Ring X is neither phenyl nor pyridyl group when Ring Y is phenyl or pyridyl group.